The FDA has started a priority review of Vertex Pharma and CRISPR Therapeutics’ exagamglogene autotemcel (exa-cel) in sickle cell disease (SCD), with a decision on approval due by 8th December.

Intensive chemo is used before treatment with gene-editing medicines, including Vertex's CRISPR Therapeutics-partnered Casgevy (exagamglogene autotemcel), which became the first based on the ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Concurrent with Lyfgenia’s approval, the FDA approved Vertex and CRISPR Therapeutics’ CRSP exagamglogene autotemcel, a CRISPR/Cas9 genome-edited cell therapy, for the treatment of SCD in ...

The approval of the first CRISPR-based therapy in late 2023—CRISPR Therapeutics and Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel or exa-cel) for sickle cell disease and β ...

In a closely competitive race, the therapy secured FDA approval ahead of time in December 2023 on the same day as Vertex/CRISPR’s Casgevy (exagamglogene autotemcel), approved for the same ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that its Chief Operating Officer, Julianne ...

Casgevy, developed by Vertex Pharmaceuticals and CRISPR Therapeutics ... CRISPR-based gene-editing therapy, Casgevy (exagamglogene autotemcel), to sickle cell disorder and beta thalassaemia ...

Next review: More evidence on exagamglogene autotemcel is being collected. After this, NICE will decide whether to recommend it for use in the NHS and update the guidance. It will be available with ...

In 2024, BOC received Vertex accreditation for its bone marrow transplant and cellular therapy services, enabling it to provide, as an accredited centre of excellence, CRISPR-based gene-editing ...